LORL yields 189.31% · ABBV yields 3.12%● Live data
📍 LORL pulled ahead of the other in Year 1
Combined, LORL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LORL + ABBV for your $10,000?
Loral Space & Communications Inc., a satellite communications company, offers satellite-based communications services to the broadcast, telecom, corporate, and government customers worldwide. As of December 31, 2019, the company provided satellite services to its customers through a fleet of 16 in-orbit geostationary satellites; and owned the Canadian Ka-band payload on the ViaSat-1 satellite. It also offers video distribution and direct-to-home (DTH) video, as well as end-to-end communications services using satellite and hybrid satellite-ground networks; and broadcast services, including DTH, video distribution and contribution, and satellite transmission services for the broadcast of video news, sports, and live event coverage. In addition, the company provides telecommunication carrier and integrator services; maritime and aeronautical services; satellite services to the Canadian government; two-way broadband Internet services; communications services to the on and off shore oil and gas, and mining industries; and satellite operator services. Further, it is involved in the installation and maintenance of the end user terminal; maintenance of the VSAT hub; and provision of satellite capacity. Additionally, the company offers consulting services related to space and earth, government studies, satellite control services, and research and development; and X-band communications services to the United States, Spanish, and allied government users. Loral Space & Communications Inc. was founded in 1996 and is headquartered in New York, New York.
Full LORL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.